Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease

CNS Drugs

Volumn 20, Issue 5, 2006, Pages 411-417

  Bordier, Philippe ^a   Garrigue, Stephane ^a   Lanusse, Stephane ^a   Margaine, Julien ^a   Robert, Frederic ^a   Gencel, Laurent ^a   Lafitte, Alexia ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLECAINIDE; PROPAFENONE; RIVASTIGMINE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHRONOTROPISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; ORTHOSTATIC HYPOTENSION; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; SYNCOPE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INDANS; MALE; PIPERIDINES; PROSPECTIVE STUDIES; RISK; SYNCOPE;

EID: 33646755862     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620050-00005     Document Type: Article

References (30)

1. Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040. J Public Health Policy 2001; 22: 88-97
2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-5
3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4-9
4. Wolfson C, Wolfson DB, Asgharian M, et al. Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-6
5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52
6. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm 1997; 54: 2805-10
7. Calvo-Romero JM, Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil. Rev Neurol 1999; 28: 1070-2
8. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812-5
9. Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558-68
10. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610-7
11. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94-9
12. Bordier P, Garrigue S, Barold SS, et al. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 2003; 5: 429-31
13. Brembilla-Perrot B, Regent MC, Hanesse B, et al. Paroxysmal atrioventricular block due to anticholinesterase therapy. [in French]. Arch Mal Coeur Vaiss 2004; 97: 1265-7
14. Jane Newby V, Anne Kenny R, McKeith IG. Donepezil and cardiac syncope: case report. Int J Geriatr Psychiatry 2004; 19: 1110-2
15. Bordier P, Lanusse S, Garrigue S, et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005; 22: 687-94
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. (DSM IV). Washington, DC: American Psychiatric Association, 1994
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44
18. Kenny RA, Shaw FE, O'Brien JT, et al. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry 2004; 75: 966-71
19. Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505
20. Consensus statement on the definition of orthostatic hypotension. pure autonomic failure and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46: 1470
21. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453-8
22. Savci V, Gurun MS, Cavun S, et al. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur J Pharmacol 1998; 346: 35-41
23. Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406-11
24. McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183-8
25. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299-313
26. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-76
27. Blass JP, Cyrus PA, Bieber F, et al. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord 2000; 14: 39-45
28. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope: update 2004. Eur Heart J 2004; 6: 467-537
29. Pavri BB, Ho RT. Syncope: identifying cardiac causes in older patients. Geriatrics 2003; 58: 26-31
30. Kenny RA. Syncope in the elderly: diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003; 14: S74-7